Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III abatacept induction and maintenance study in active ulcerative colitis
NL-OMON30798Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abatacept in autoimmune colitis (4 arms), sponsored by Bristol Myers Squibb. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
abatacept
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON30798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30798.